Abstract
The inability of preclinical research methods to fully reflect human biology leads to significant challenges in drug development, including high costs, time losses, and ethical concerns. Consequently, regulatory shifts such as the European Parliament’s calls to prioritize non-animal methods and the enactment of the Food and Drug Administration Modernization Act 2.0 in the United States have accelerated the transition toward alternative research models. In this context, artificial intelligence (AI) has emerged not merely as a supportive technology, but as a fundamental component of preclinical modeling. Machine learning and deep learning methods provide researchers with substantial advantages in areas such as biomedical data analysis, evaluation of drug candidates, toxicity prediction, and interpretation of imaging data. In particular, computer-based toxicity and drug evaluation systems help identify failing drug candidates at an early stage, thereby accelerating experimental processes and reducing animal use. In addition, digital twin technologies generate virtual human models using personalized clinical and biological data, enabling different treatment scenarios to be tested safely. Organ-on-chip systems, functioning as miniaturized laboratory models of human organs, offer a more realistic means of examining drug effects. Through AI-powered automation systems, these platforms are becoming faster, more scalable, and more efficient. Furthermore, the integrated analysis of genetic, metabolic, and imaging data enables more comprehensive modeling of biological processes and strengthens efforts to predict patient-specific drug responses in advance. Nevertheless, challenges such as data heterogeneity, model reliability, and interpretability remain significant limitations. In conclusion, AI stands out not merely as a tool for accelerating research processes, but as a new scientific paradigm aimed at reducing animal experimentation, developing models that more closely reflect human biology, and supporting personalized medicine applications.
Keywords:
Artificial intelligence, preclinical modeling, drug development, personalized medicine, tumor imaging
References
1Hartung T. The (misleading) role of animal models in drug development. Front. Drug Discov. 2024;4:1355044.
2European Parliament. Resolution on plans and actions to accelerate the transition to innovation without the use of animals in research, regulatory testing and education. Procedure No: 2021/2784(RSP), Reference No: T9-0387/2021. Legislative Observatory [Internet]. 2021. Available from: https://oeil.europarl.europa.eu/oeil/en/procedure-file?reference=2021/2784(RSP)
3US Congress. S.5002 - FDA Modernization Act 2.0. 117th Congress (2021-2022). Congress.gov [Internet]. 2022. Available from: https://www.congress.gov/bill/117th-congress/senate-bill/5002
4Holey VS, Baitule AW. A wide application of artificial intelligence in pharma field. Asian Journal of Pharmaceutical Research. 2024;14:403-410.
5Uriti SV. A systematic review of AI-driven innovations in drug development, precision medicine, and healthcare. Journal of Pharma Insights and Research. 2025;3:220-230.
6Gangwal A, Lavecchia A. Artificial intelligence in preclinical research: enhancing digital twins and organ-on-chip to reduce animal testing. Drug Discov Today. 2025;30:104360.
7Kandhare P, Kurlekar M, Deshpande T, Pawar A. A review on revolutionizing healthcare technologies with AI and ML applications in pharmaceutical sciences. Drugs Drug Candidates. 2025;4:9.
8Qadri YA, Shaikh S, Ahmad K, Choi I, Kim SW, Vasilakos AV. Explainable artificial intelligence: a perspective on drug discovery. Pharmaceutics. 2025;17:1119.
9Mian SM, Khan MS, Shawez M, Kaur A. Artificial intelligence (AI), machine learning (ML) & deep learning (DL): a comprehensive overview on techniques, applications and research directions. In: 2024 2nd International Conference on Sustainable Computing and Smart Systems (ICSCSS); 2024; Coimbatore, India. New York: IEEE; 2024. p. 1404-1409.
10Del Rosso MP, Ullo S, Sebastianelli A, et al. Artificial intelligence, machine learning and deep learning. London: Institution of Engineering and Technology; 2021. p. 39-61.
11Hügle M, Omoumi P, van Laar JM, Boedecker J, Hügle T. Applied machine learning and artificial intelligence in rheumatology. Rheumatol Adv Pract. 2020;4:rkaa005.
12Esengönül M, Marta A, Beirão J, Pires IM, Cunha A. A systematic review of artificial intelligence applications used for inherited retinal disease management. Medicina (Kaunas). 2022;58:504.
13Ferreira FJN, Carneiro AS. AI-driven drug discovery: a comprehensive review. ACS Omega. 2025;10:23889-23903.
14Ekert JE, Deakyne J, Pribul-Allen P, et al. Recommended Guidelines for Developing, Qualifying, and Implementing Complex In Vitro Models (CIVMs) for Drug Discovery. SLAS Discov. 2020;25:1174-1190.
15LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521:436-444.
16Tropsha A, Isayev O, Varnek A, Schneider G, Cherkasov A. Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR. Nat Rev Drug Discov. 2024;23:141-155.
17Besharatifard M, Vafaee F. A review on graph neural networks for predicting synergistic drug combinations. Artif Intell Rev. 2024;57:49.
18Hashimoto F, Onishi Y, Ote K, Tashima H, Reader AJ, Yamaya T. Deep learning-based PET image denoising and reconstruction: a review. Radiol Phys Technol. 2024;17:24-46.
19Zhang J, Li H, Zhang Y, Huang J, Ren L, Zhang C, Zou Q, Zhang Y. Computational toxicology in drug discovery: applications of artificial intelligence in ADMET and toxicity prediction. Brief Bioinform. 2025;26:bbaf533. Erratum in: Brief Bioinform. 2025;26:bbaf708.
20Deng S, Li C, Cao J, et al. Organ-on-a-chip meets artificial intelligence in drug evaluation. Theranostics. 2023;13:4526-4558.
21Zhou L, Chen S, Liu J, et al. When artificial intelligence meets organoids and organs-on-chips: game-changer for drug discovery and development? The Innovation Life. 2025;3:100115.
22Patel CN, Kumar SP, Rawal RM, Patel DP, Gonzalez FJ, Pandya HA. A multiparametric organ toxicity predictor for drug discovery. Toxicol Mech Methods. 2020;30:159-166.
23Bueso-Bordils JI, Antón-Fos GM, Martín-Algarra R, Alemán-López PA. Overview of computational toxicology methods applied in drug and green chemical discovery. J Xenobiot. 2024;14:1901-1918.
24Wenzel J, Matter H, Schmidt F. Predictive multitask deep neural network models for ADME-tox properties: learning from large data sets. J Chem Inf Model. 2019;59:1253-1268.
25Kearnes S, Goldman B, Pande V. Modeling industrial ADMET data with multitask networks. arXiv [stat.ML]. 2016;1606.08793.
26Venkataraman M, Rao GC, Madavareddi JK, Maddi SR. Leveraging machine learning models in evaluating ADMET properties for drug discovery and development. ADMET DMPK. 2025;13:2772.
27Grieves M. Digital twin: manufacturing excellence through virtual factory replication [White paper]. 2014. p. 1-7.
28Erol T, Mendi AF, Doğan D. Digital transformation revolution with digital twin technology. In: 2020 4th International Symposium on Multidisciplinary Studies and Innovative Technologies (ISMSIT); 2020. p. 1-7.
29Kritzinger W, Karner M, Traar G, Henjes J, Sihn W. Digital twin in manufacturing: a categorical literature review and classification. IFAC PapersOnLine. 2018;51:1016-1022.
30Stefanicka-Wojtas D, Kurpas D. Personalised medicine-implementation to the healthcare system in Europe (Focus Group Discussions). J Pers Med. 2023;13:380.
31Gonçalves M, Barata P, Vale N. From population-based PBPK to individualized virtual twins: clinical validation and applications in medicine. J Clin Med. 2026;15:1210.
32Jacoby M, Usländer T. Digital twin and internet of things—current standards landscape. Appl. Sci. 2020;10:6519.
33Shah N, Nagar J, Desai K, Bhatt N, Bhatt N, Mewada H. Machine learning-enabled digital twins for diagnostic and therapeutic purposes. In: Tyagi AK, editor. Artificial Intelligence-Enabled Blockchain Technology and Digital Twin for Smart Hospitals. Beverly: Wiley; 2024. p. 77-97.
34Björnsson B, Borrebaeck C, Elander N, et al. Digital twins to personalize medicine. Genome Medicine. 2020;12:4.
35Bruynseels K, Santoni de Sio F, van den Hoven J. Digital twins in health care: ethical implications of an emerging engineering paradigm. Front Genet. 2018;9:31.
36Vallée A. Digital twin for healthcare systems. Front Digit Health. 2023;5:1253050.
37Hwang T, Kwon O, Lim B, et al. Clinical application of virtual antiarrhythmic drug test using digital twins in patients who recurred atrial fibrillation after catheter ablation. Europace. 2023;25(Suppl 1):euad122.076.
38Weickenmeier J, Jucker M, Goriely A, Kuhl E. A physics-based model explains the prion-like features of neurodegeneration in Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Journal of the Mechanics and Physics of Solids. 2019;124:264-281.
39Khan S, Alzaabi A, Ratnarajah T, Arslan T. Novel statistical time series data augmentation and machine learning based classification of unobtrusive respiration data for respiration Digital Twin model. Comput Biol Med. 2024;168:107825.
40Herrgårdh T, Simonsson C, Ekstedt M, et al. A multi-scale digital twin for adiposity-driven insulin resistance in humans: diet and drug effects. Diabetol Metab Syndr. 2023;15:250.
41Eminaga O, Abbas M, Kunder C, et al. Critical evaluation of artificial intelligence as a digital twin of pathologists for prostate cancer pathology. Sci Rep. 2024;14:5284.
42Pandey H, Amod A, Shivang. Digital twin ecosystem for oncology clinical operations. arXiv [cs.AI]. 2024;2409.17650.
43Sel K, Hawkins-Daarud A, Chaudhuri A, et al. Survey and perspective on verification, validation, and uncertainty quantification of digital twins for precision medicine. NPJ Digit Med. 2025;8:40.
44Bédard P, Gauvin S, Ferland K, et al. Innovative human three-dimensional tissue-engineered models as an alternative to animal testing. Bioengineering (Basel). 2020;7:115.
45Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022;23:467-491.
46Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662-1668.
47Leung CM, de Haan P, Ronaldson-Bouchard K, et al. A guide to the organ-on-a-chip. Nature Reviews Methods Primers. 2022;2:33.
48Picollet-D’hahan N, Zuchowska A, Lemeunier I, Le Gac S. Multiorgan-on-a-chip: a systemic approach to model and decipher inter-organ communication. Trends Biotechnol. 2021;39:788-810.
49Riordon J, Sovilj D, Sanner S, Sinton D, Young EWK. Deep learning with microfluidics for biotechnology. Trends Biotechnol. 2019;37:310-324.
50McIntyre D, Lashkaripour A, Fordyce P, Densmore D. Machine learning for microfluidic design and control. Lab Chip. 2022;22:2925-2937.
51Low LA, Tagle DA. Microphysiological systems (“organs-on-chips”) for drug efficacy and toxicity testing. Clin Transl Sci. 2017;10:237-239.
52Li J, Chen J, Bai H, et al. An overview of organs-on-chips based on deep learning. Research (Wash D C). 2022;2022:9869518.
53De Chiara F, Ferret-Miñana A, Ramón-Azcón J. The synergy between organ-on-a-chip and artificial intelligence for the study of NAFLD: from basic science to clinical research. Biomedicines. 2021;9:248.
54Friedman N, Geiger D, Goldszmidt M. Bayesian network classifiers. Mach Learn. 1997;29:131-163.